FATE Stock Analysis: Buy, Sell, or Hold?
FATE - Fate Therapeutics, Inc.
$1.22
-0.02 (-1.61%)
▼
5d:
-0.81%
30d:
-15.86%
90d:
+24.16%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Distribution
FATE is up 3.5% this week, but smart money is buying puts. Top strike: $1 2026-05-15 with 192 OI. Put ratio: 100% View Scanner →
Strength: 6.7/10
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: FATE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: FATE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $1.22, which is considered fair relative to its 30-day fair value range of $1.13 to $1.45.
Technical Outlook: Technically, FATE is in a downtrend. Immediate support is located at $1.06, while resistance sits at $1.31.
Market Sentiment: FATE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.94 (+305.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FATE is in a downtrend. Immediate support is located at $1.06, while resistance sits at $1.31.
Market Sentiment: FATE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.94 (+305.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.13 -
$1.45
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 305.3% below Wall St target ($4.94)
Fair Price Analysis
30-Day Fair Range
$1.13 -
$1.45
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.07
Resistance Level
$1.31
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.16
Wall Street Target
$4.94
(+305.3%)
Revenue Growth (YoY)
-26.4%
Share & Embed Analysis
Last updated: April 03, 2026 5:07 AM ET
Data refreshes hourly during market hours. Next update: 6:07 AM
Data refreshes hourly during market hours. Next update: 6:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Bahram Valamehr
SELL
5190 shares
2026-01-09
Cindy Tahl
SELL
10589 shares
2026-01-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
